SHR-1826 + SHR-4642

SHR-1826 + SHR-4642 is an investigational combination regimen under clinical development for the treatment of advanced solid tumors. **SHR-1826** is an antibody-drug conjugate (ADC) targeting c-Met, a receptor tyrosine kinase implicated in tumor growth and metastasis. ADCs function by delivering cytotoxic payloads selectively to tumor cells expressing specific antigens—in this case, c-Met—leading to targeted cell death[2][8]. **SHR-4642** (also referenced as HRS-4642) is a highly selective, potent, non-covalent inhibitor of KRAS G12D, a common oncogenic mutation in solid tumors, particularly pancreatic, colorectal, and lung cancers[1][9]. This combination is being evaluated for its synergistic anti-tumor effects in subjects with malignant solid tumors, aiming to target parallel oncogenic pathways and overcome resistance mechanisms. Both drugs are in early-phase clinical trials, with current investigation focused on safety, tolerability, and preliminary efficacy in advanced, refractory solid tumors[1][2][8][10].

Other names

HRS-4642HRS4642HRS 4642